Format

Send to

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Disord. 2012;33(4):219-25. doi: 10.1159/000338546. Epub 2012 May 14.

Plasma methionine sulfoxide in persons with familial Alzheimer's disease mutations.

Author information

1
Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California at Los Angeles, Los Angeles, CA 90095-7334, USA.

Abstract

BACKGROUND:

Convergent evidence suggests that oxidative stress plays a central role in the pathology of Alzheimer's disease (AD). We asked if consequently, oxidation of methionine residues to methionine sulfoxide (MetO) was increased in plasma proteins of persons carrying familial AD (FAD) mutations.

METHODS:

Plasma was collected from 31 persons from families harboring PSEN1 or APP mutations. Using Western blot analysis with a novel anti-MetO polyclonal antibody, MetO levels were measured and compared between FAD mutation carriers (MCs) and non-mutation carrying (NCs) kin.

RESULTS:

A MetO-positive 120-kDa gel band distinguished FAD MCs and NCs (mean 11.4 ± 2.8 vs. 4.0 ± 3.1, p = 0.02). In a subset of subjects for whom both measurements were available, MetO levels correlated well with plasma F2-isoprostane (r = 0.81, p < 0.001) and superoxide dismutase 1 (r = 0.52, p = 0.004) levels.

CONCLUSION:

Our data provide evidence for elevated MetO levels in persons carrying FAD mutations that correlate with other indices of oxidative stress and suggest that plasma oxidative stress markers may be useful for diagnosis of AD.

PMID:
22584618
PMCID:
PMC3568669
DOI:
10.1159/000338546
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Support Center